Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

School of Breast Oncology Offers Intensive Retreat

December 1st 2011

Joyce A. O'Shaughnessy explores the 8th Annual School of Breast Oncology, an interactive program designed to immerse oncology professionals in the latest science.

Controversies in Treatment Spur Another Look at Z11

November 30th 2011

The Z11 study suggests that there is no difference in survival among patients with breast cancer who did not undergo a recommended surgical treatment.

FDA Says Avastin Not Safe or Effective for Patients With Breast Cancer

November 18th 2011

The FDA commissioner announced the withdrawal of its approval for bevacizumab (Avastin) to treat patients with breast cancer.

Dr. Brufsky Advises Doctors on Avastin for Breast Cancer

November 18th 2011

Dr. Adam Brufsky from the University of Pittsburgh School of Medicine Advises Doctors on Bevacizumab (Avastin) for Breast Cancer

Dr. DuPree Provides Z11 Trial Takeaway Points

November 17th 2011

Dr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points

Dr. White Discusses the Z11 Trial Radiation Findings

November 15th 2011

Dr. Julia R. White from the Medical College of Wisconsin, Discusses the Z11 Trial Radiation Findings

Dr. Brufsky Discusses Bevacizumab Benefits in TNBC

November 15th 2011

Dr. Adam Brufsky from University of Pittsburgh School of Medicine, Discusses Bevacizumab Benefits in TNBC

Advances in Breast Cancer Treatment: Expert Panel Discussion of Challenging Cases

November 7th 2011

The following cases were discussed at the 10th International Congress on the Future of Breast Cancer, which was held in Coronado, California, from August 4-7, 2011.

3 ASCO Updates Tackle Treatment and Supportive Care Questions

November 4th 2011

ASCO endorses a Canadian agency's outlook on ovarian ablation, chemotherapy limits for stage IV lung cancer patients, and supportive care antiemetic therapies.

Dr. Goldstein on the Fox Chase Breast Evaluation Center

October 28th 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center

Trastuzumab Is Cardiotoxic in Some Elderly Patients With Breast Cancer

October 27th 2011

Older patients with breast cancer who have a history of heart disease and/or diabetes have an increased risk of cardiotoxicity during treatment with trastuzumab.

Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer

October 26th 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Guidelines for Genetic Counseling or BRCA 1/2 Testing Are Often Ignored

October 25th 2011

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

Dr. Bardwell on Cancer-Related Variables and Depression

October 25th 2011

Dr. Wayne Bardwell from UCSD Cancer Center on Cancer-Related Variables and Depression

Insights on Avastin: Patient Selection Is Key

October 18th 2011

The controversy over the breast cancer indication for Avastin culminated in June when the ODAC voted after an unusual and emotional 2-day hearing to uphold a prior recommendation to withdraw the label indication.

Dr. Rugo on the Efficacy of Bevacizumab in Breast Cancer

October 17th 2011

Dr. Hope S. Rugo from the University of California, San Francisco on the Efficacy of Bevacizumab in Breast Cancer

Dr. Morrow Discusses the Z11 Trial Focus on Morbidity

October 11th 2011

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Discusses the Z11 Trial Focus on Morbidity

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

October 11th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Efforts to Improve HER2 Testing Continue ASCO Panelist Sees Progress

October 11th 2011

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

Effectiveness of Adriamycin Questioned in the Treatment of Patients With HER2-Positive Breast Cancer

October 7th 2011

HER2-positive women can be effectively treated with Herceptin (trastuzumab injection) without the use of Adriamycin.